rs11061946 — ADIPOR2

ADIPOR2 rs11061946 — A Rare Signal in the Adiponectin Receptor

Adiponectin is one of the few adipokines that works against metabolic disease: it rises with fat loss, improves insulin sensitivity, suppresses hepatic glucose production, and triggers fatty acid oxidation¹¹ fatty acid oxidation
the breakdown of fat for fuel, primarily in liver and muscle through the PPARα pathway. The receptor through which adiponectin acts in the liver is ADIPOR2 (Adiponectin Receptor 2, gene symbol ADIPOR2, chromosome 12p13.31). Unlike its partner ADIPOR1 — the predominant muscle receptor — ADIPOR2 is most abundantly expressed in hepatic tissue, where it couples adiponectin signaling to the PPARα pathway²² PPARα pathway
Peroxisome proliferator-activated receptor alpha, a nuclear receptor that upregulates enzymes for fatty acid β-oxidation and downregulates hepatic gluconeogenesis and pro-inflammatory gene programs. Disrupting AdipoR2 in mice impairs hepatic fatty acid oxidation, worsens diet-induced insulin resistance, and elevates fasting glucose, establishing a clear causal role for the receptor in metabolic homeostasis.

rs11061946 is an intronic variant located in intron 1 of ADIPOR2. It does not change any amino acid and has not been shown to alter splicing or gene expression in available functional studies. It may be a marker in linkage disequilibrium with a nearby causal variant, or it may itself influence chromatin accessibility or transcription factor binding in a context not yet captured by available expression datasets.

The Mechanism

The variant sits in intron 1 of ADIPOR2³³ intron 1 of ADIPOR2
The first intron, between the first and second coding exons; intronic variants can affect mRNA splicing, act as regulatory elements, or simply be neutral markers for nearby functional variants. No allele-specific differences in ADIPOR2 mRNA expression were detected in peripheral blood mononuclear cells or subcutaneous adipose tissue in the Genobin sub-study (56 subjects). The authors of the Finnish DPS paper explicitly noted that rs11061946 and its LD partner rs11061973 "are intronic SNPs, have no known functional significance, and may therefore be merely markers in LD with a true causal variant." The working hypothesis is that reduced or altered ADIPOR2 activity in rare TT homozygotes impairs hepatic adiponectin signaling, reducing PPARα-driven fatty acid oxidation and leaving the liver less able to suppress gluconeogenesis — a mechanism consistent with T2D progression, but not yet mechanistically demonstrated for this variant specifically.

rs11061946 is in strong linkage disequilibrium (r² = 0.674) with rs11061973, another intronic ADIPOR2 variant. The two SNPs co-segregate tightly: all five TT homozygotes at rs11061946 in the Finnish DPS were also AA homozygotes at rs11061973, meaning the signal may reflect a haplotype effect across this region of intron 1 rather than either SNP individually.

The Evidence

The primary evidence comes from the Finnish Diabetes Prevention Study (DPS)⁴⁴ Finnish Diabetes Prevention Study (DPS)
A randomized controlled trial of 484 overweight adults with impaired glucose tolerance; intervention arm received intensive diet and exercise counseling, control arm received general information; median follow-up 7 years. Eight ADIPOR2 SNPs were genotyped. In a Cox proportional-hazards model adjusted for age, sex, study arm, baseline waist circumference, and fasting glucose:

• TT genotype (n = 5): HR = 5.54 (95% CI 2.01–15.23), p = 0.001
• CT genotype (n = 49): HR = 0.71 (95% CI 0.41–1.21), p = 0.206
• CC genotype (n = 428): reference

The TT finding is striking numerically, but critical limitations apply. Only five individuals carried the TT genotype across the entire study, making the confidence interval very wide. The dominant inheritance model (CT + TT vs. CC) showed no significant association, indicating the risk is concentrated in the rare homozygote and does not manifest in heterozygotes. The study has not been replicated in an independent cohort, and a q-value (false discovery rate) correction of 0.369 for the TT result indicates that at this sample size, the finding does not survive multiple testing correction. rs11061946 also deviated from Hardy-Weinberg equilibrium in this Finnish sample — the authors retained it in analysis but flagged this as potentially reflecting small-sample chance deviation.

No association was found with cardiovascular disease outcomes in the same cohort. Broader ADIPOR2 SNP studies in UK populations (PMID 17216283) and Caucasian cohorts (PMID 16505255) did not report rs11061946 specifically, and none of 24 ADIPOR1/R2 polymorphisms were associated with T2D or insulin phenotypes in the larger UK replication sets.

Practical Actions

For the ~1% of people who are TT homozygotes, the Finnish DPS data suggest a substantially elevated hazard of progressing from impaired glucose tolerance to type 2 diabetes, though this signal has not been independently replicated. For CT heterozygotes (~14%), no statistically significant risk above baseline was observed.

Given that ADIPOR2 mediates adiponectin-driven hepatic fatty acid oxidation through PPARα, the metabolically meaningful intervention for anyone with impaired glucose tolerance — independent of genotype — is to support adiponectin activity. Adiponectin rises with weight loss, aerobic training, caloric restriction, and omega-3 fatty acid intake. For TT homozygotes specifically, the implication is that if receptor-level function is compromised, downstream metabolic support becomes more important: prioritizing dietary patterns that minimize hepatic fat accumulation (the chief driver of hepatic insulin resistance) and that avoid further suppression of adiponectin. Fasting glucose, 2-hour glucose tolerance, and HbA1c monitoring at the intervals used for clinical pre-diabetes management apply.

Interactions

rs11061946 is in moderate LD (r² = 0.674) with rs11061973, another intronic ADIPOR2 variant on the same haplotype block. The five TT individuals in the Finnish DPS were uniformly AA at rs11061973, suggesting a shared haplotype drives the risk rather than either variant independently. If both rs11061946 TT and rs11061973 AA are present together, the signal represents the same underlying haplotype — not an independent combinatorial risk.

The broader adiponectin pathway involves ADIPOQ (the adiponectin gene itself), ADIPOR1 (the complementary muscle-expressed receptor), and downstream transcription factors PPARA and PPARGC1A. Variants in these genes that reduce circulating adiponectin or impair receptor coupling could compound the effect of reduced ADIPOR2 activity, though no published compound analysis covers this specific combination.

Supervisor interaction proposal: rs11061946 TT + rs11061937 (the companion ADIPOR2 intronic variant) — if both variants tag a disrupted ADIPOR2 haplotype, combined homozygosity may indicate a more comprehensive ADIPOR2 functional deficit. Evidence is currently speculative (no compound study exists); propose as an interaction candidate for future investigation rather than a compound action today.